Servicio de Farmacología Clínica, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat (Barcelona), España.
Servicio de Farmacología Clínica, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat (Barcelona), España; Unidad de Farmacología, Departamento de Patología y Terapéutica Experimental, Facultad de Medicina y Ciencias de la Salud, Universidad de Barcelona, L'Hospitalet de Llobregat (Barcelona), España.
Med Clin (Barc). 2024 Dec 13;163(11):557-563. doi: 10.1016/j.medcli.2024.07.019. Epub 2024 Oct 8.
Acute pancreatitis (AP) is an inflammatory disease with multiple etiologies, and the emergence of complications. Between 0.1-5% of cases are attributed to drugs. The absence of specific characteristics complicates the diagnosis and treatment of drug-induced AP. Reviewing patients admitted with the diagnosis of drug-induced AP can provide information and improve its management.
This is a descriptive, observational, and retrospective study. All patients admitted to the Hospital Universitari de Bellvitge between June 2007 and March 2023 with suspected drug-induced AP were included. The data were obtained from the hospital pharmacovigilance program database.
Thirty-eight patients with suspected drug-induced AP were identified, representing 0.62% of all adverse drug reactions (n=6.085). Of these, 65.8% (n=25) had a single suspected drug. The median latency period for the onset of adverse drug reactions was 160.5 days (IQR: 18-582 days), and the median hospital stay was 5 days (IQR: 3-7 days). Fifty-nine suspected drugs were identified, involving 26 active principles. Azathioprine and atorvastatin were the most frequent, with 9 cases each (15.2%), followed by enalapril with 8 cases (13.6%). Drug etiology was assessed in 23 cases (60.5%), and the suspected drug was discontinued in all cases. There was one fatal case documented (2.63%).
This study can contribute to better understanding of drug-induced pancreatitis episodes. We propose a diagnostic algorithm that includes the assessment of the drug as a possible cause.
急性胰腺炎(AP)是一种具有多种病因和并发症的炎症性疾病。其中 0.1-5%的病例归因于药物。由于缺乏特定的特征,药物性 AP 的诊断和治疗变得复杂。回顾诊断为药物性 AP 的患者可提供信息并改善其管理。
这是一项描述性、观察性和回顾性研究。纳入 2007 年 6 月至 2023 年 3 月期间因疑似药物性 AP 住院的所有患者。数据来自医院药物警戒计划数据库。
共发现 38 例疑似药物性 AP 患者,占所有药物不良反应的 0.62%(n=6085)。其中 65.8%(n=25)的患者存在单一可疑药物。不良药物反应的潜伏期中位数为 160.5 天(IQR:18-582 天),住院时间中位数为 5 天(IQR:3-7 天)。确定了 59 种可疑药物,涉及 26 种活性成分。其中,巯嘌呤和阿托伐他汀最常见,各有 9 例(15.2%),其次是依那普利,有 8 例(13.6%)。在 23 例(60.5%)中评估了药物病因,所有病例均停用可疑药物。有 1 例死亡病例(2.63%)。
本研究有助于更好地了解药物性胰腺炎发作。我们提出了一个诊断算法,包括评估可疑药物作为可能的病因。